None listed
Conditions
Interventions
Dietary Supplement : Test food: Phellinus linteus(sanghuang) extract (1,000 mg/day)
Control food: placebo (dextrin 1,000 mg/day)
Take orally for 8 weeks, twice a day, 1 capsule at a time.
Sponsors
Cheonan Korean Medicine Hospital of Daejeon University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men and women aged 20 to 65 years old 2. Peripheral blood WBC of 3×1000/µl or more and less than 10×1000/µl 3. Those who have had upper respiratory tract infections or cold symptoms, a typical disease that can cause upper respiratory tract infections, more than two times within one year before the start of the test 4. A person who has agreed to participate in this test and signed a written consent form by the subject (or legal representative) voluntarily
Exclusion criteria
Exclusion criteria: 1. Those who are currently being treated for clinically significant acute or chronic cardio-cerebrovascular system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, nervous system, musculoskeletal disease, psychotic, infectious and hematologic/neoplastic diseases, etc. You can participate in the research at the discretion of the research director considering the status of 2. Those with uncontrolled hypertension (160/100mmHg or more, measured after 10 minutes of rest for the subject) 3. Patients with uncontrolled diabetes (fasting glucose 126mg/dL or higher, or starting a new drug due to diabetes within 3 months) 4. Those whose AST(GOT) or ALT(GPT) blood level is 3 times or more than the normal upper limit of the relevant organ7,8,9 5. Creatinine blood levels exceeding 2.4mg/dL for men and 1.8mg/dL for women 6. Those who have consumed or are ingesting health functional foods that may affect immunity within 2 weeks before screening 7. Those who complain of severe gastrointestinal symptoms such as heartburn and indigestion 8. Pregnant, lactating or planning to become pregnant during the study period 9. Those who are sensitive or allergic to test food related foods 10. Those who plan to participate in other studies during this study 11. Those who received other study drugs within 4 weeks of starting this study 12. Those who the researcher deems unsuitable for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NK cell activity | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-1ß, IL-2, IL-6, IL-12;IgG1, IgG2, IgM | — |
Countries
Korea, Republic of
Contacts
Public ContactYong Ho Ku
Cheonan Korean Medicine Hospital of Daejeon University
Outcome results
None listed